Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 258Breast Neoplasms 218Lung Neoplasms 207Glioblastoma 202Head and Neck Neoplasms 193Prostatic Neoplasms 179Squamous Cell Carcinoma of Head and Neck 171Lymphoma 152Rectal Neoplasms 139Esophageal Neoplasms 125Central Nervous System Neoplasms 122Leukemia 111Brain Neoplasms 107Pancreatic Neoplasms 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 87Esophageal Squamous Cell Carcinoma 84Sarcoma 82Uterine Cervical Neoplasms 81Neoplasms 81Lymphoma, Follicular 81Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Non-Hodgkin 75Hodgkin Disease 74Glioma 68Burkitt Lymphoma 67Colorectal Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 63Astrocytoma 63Neoplasm Metastasis 60

Interventions

Radiotherapy 4Immune Checkpoint Inhibitors 4famitinib 1camrelizumab 1aflutinib 1Oxaliplatin 1Nivolumab 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced NSCLC × Radiotherapy × Clear all
NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡